# Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

> **NCT03535246** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** Engineered Immune Cells

## Key facts

- **NCT ID:** NCT03535246
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535246, "Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03535246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*